

Attorney Docket No. P67813US1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of: VON DER KAMMER et al.

Serial No. 10/511,096

Filed: October 14, 2004

For: DIAGNOSTIC AND THERAPEUTIC USE OF A GOLGI PROTEIN FOR NEURODEGENERATIVE DISEASES

TRANSMITTAL

Mail Stop Sequence
 Commissioner for Patents
 P.O. Box 1450
 Alexandria, VA 22313-1450

Sir:

Transmitted herewith please find:


- ☒ Response/Statement Under 37 CFR 1.821(g), PTO Notice (copy), CRF of Sequence Listing.
- ☐ Petition for extension of time
- ☐ Fee payment ☐ Payment Form PTO-2038 (credit card) for \$ * is attached.
- ☐ Charge \$ * to Deposit Account No. 06-1358.
- ☐ Small entity status established in connection with the subject application.

Fee Calculation					
Excess Claims					
	Nº of Claims	Highest Nº Paid For	Excess Claims	Small Entity Fee	Large Entity Fee
Total	*	⊖ * =	0	⊗ \$9 = \$	⊗ \$18 = \$
Ind.	*	⊖ * =	0	⊗ \$42 = \$	⊗ \$84 = \$
[] Multiple Dependent Claims (1 st Filing)				⊕ \$140 =	⊕ \$280 = \$
Extension of Time Fee				\$	\$
Total Fee Due				??	??

- ☒ If a petition for extension of time is necessary, but not enclosed, then this acts as the petition. Charge any fees additionally necessary in connection herewith to Deposit Account No. 06-1358.

JACOBSON HOLMAN PLLC
 400 Seventh Street, N. W.
 Washington, D.C. 20004-2201
 Tel. (202) 638-6666
 Fax (202) 393-5350
 Date: May 31, 2005

By


 William E. Player
 Registration No. 31,409



4/6/05
 WEP
 P67813US1
 UNITED STATES PATENT AND TRADEMARK OFFICE

TC 4-605

UNITED STATES DEPARTMENT OF COMMERCE
 United States Patent and Trademark Office
 Address: COMMISSIONER FOR PATENTS
 P.O. Box 1450
 Alexandria, Virginia 22313-1450
 www.uspto.gov

U.S. APPLICATION NUMBER NO.	FIRST NAMED APPLICANT	ATTY. DOCKET NO.
10/511,096	Heinz Von Der Kammer	P67813US1

00136
 JACOBSON HOLMAN PLLC
 400 SEVENTH STREET N.W.
 SUITE 600
 WASHINGTON, DC 20004

**SEQUENCE
 LISTING**

JACOBSON HOLMAN PLLC
 Response Due On Or Before
 5 / 31 / 05
 Month Day Year

INTERNATIONAL APPLICATION NO.	
PCT/EP03/03958	
I.A. FILING DATE	PRIORITY DATE
04/16/2003	04/14/2002

CONFIRMATION NO. 6145
 371 FORMALITIES LETTER

 OC000000015610867

Date Mailed: 03/31/2005

NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application clearly fails to comply with the requirements of 37 CFR. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing", an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment directing its entry into the application. Applicant must also provide a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.
- The paper or compact disc copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 CFR 1.821(e). Applicant must provide a substitute paper or compact disc copy of the "Sequence Listing", as well as an amendment directing its entry into the application OR a substitute computer readable form (CRF) copy of the "Sequence Listing". These two items must be the same. Applicant must also provide a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000).

For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:

- For Rules Interpretation, call (571) 272-0951
- For Patent Software Program Help, call Patent EBC at 1-866-217-9197 or directly at 703-305-3028 / 703-308-6845 between the hours of 6 a.m. and 12 midnight, Monday through Friday, EST.

- Send e-mail correspondence for Patent Software Program Help @ ebc@uspto.gov

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

*A copy of this notice **MUST** be returned with the response.*

VONDA M WALLACE

Telephone: (703) 308-9140 EXT 225

PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
10/511,096	PCT/EP03/03958	P67813US1

FORM PCT/DO/EO/922 (371 Formalities Notice)

FIRST CLASS MAIL • FIRST CLASS MAIL • FIRST CLASS MAIL

FROM

Applicant von Der Kammer et al.

Appln. Title Diagnostic and Therapeutic
Use of a Golgi Protein for
Neurodegenerative Diseases

Date recorded May 31, 2005

Operating MS-Windows
System

TO Atty. Ref. P67813US1

Appln. No. 10/511,096

Filing Date October 14, 2004

Jiffy™ Disk U.

- Do not bend or fold
- Avoid exposure to magnetic fields
- Lined with anti-static recycled polyethylene foam

FIRST CLASS MAIL • FIRST CLASS MAIL • FIRST CLASS MAIL